How many investments has Mission Bay Capital made?

Mission Bay Capital has 34 tracked investments, 3 of which have exited.

What stage does Mission Bay Capital invest at?

Mission Bay Capital invests at the Pre-Seed, Seed, Series A, Late Stage stages.

What sectors does Mission Bay Capital focus on?

Mission Bay Capital focuses on Biotech, Climate Tech, Deep Tech, Healthtech, Medical Devices.

Where is Mission Bay Capital located?

Mission Bay Capital is headquartered in San Francisco, US.

Who does Mission Bay Capital co-invest with?

Mission Bay Capital most often shares deals with Mission Biocapital, Berkeley Catalyst, OUP (Osage University Partners), among 70 tracked co-investors.

Mission Bay Capital

Venture capitaloperating company · company profile

San Francisco · Pre-Seed–Late Stage · 13 people tracked

Also known as AWESOME ENABLERS, L.L.C. · MBC FII MANAGEMENT, LLC · Mission Wealth Management, Lp

★ Follow + Add to CRM ⤳ Find an introduction

Find your way into Mission Bay Capital

2,253 people in our graph share verified history with the Mission Bay Capital team — schools, employers, funds. One of them is your warm intro.

Zach Collinsunlockedknows Robert Blazej · together at MBC Biolabs (overlapped)

knows the team · via Neon Labs

knows the team · via XSeed Capital

×9knows the team · via Mission Biocapital

✨ Fox Verdict

Investment thesis

Mission Bay Capital aims to help entrepreneurial scientists turn ideas into successful companies, viewing startups as an efficient engine for positive change. It provides critical early-stage capital to prove out technologies at a point when other investors are hesitant. Through its MBC BioLabs incubator, the firm offers state-of-the-art laboratory facilities so startups can begin experiments immediately, helping founders operate efficiently. It further supports portfolio growth through a network of advisors, industry partners, university colleagues, and co-investors. The firm concentrates on science-driven ventures tackling oversized problems including chronic diseases and global environmental challenges.

Invests inBiotech Climate Tech Deep Tech Healthtech Medical Devices San Francisco United States

Source: firm website, verified Sep 22, 2026.

Stage

Pre-Seed–Late Stage

San Francisco, California, US

Instruments

Equity

Founded

2009

AUM

$90M

VC funds

Tracked investments

Unicorns

IPOs

Acquisitions

Team · 13 people

from the firm's website & curated & public directories

Robert Blazej· Partner· San Franciscoin

Robert Blazej, a UCSF/UC Berkeley bioengineer PhD who co‑founded Allopartis and led its Novozymes integration, has daily exposure to early scientific founders through dual partner/director roles in a life‑science incubator.

r•••@missionbiocapital.comreveal

Peter Parker· Venture Partner, Mission Bay Capital· Cambridge, Massachusettsin

Peter Parker is a VC who co‑founded LabCentral, created the influential wet‑lab coworking model, built lab infrastructure and serves on Massachusetts Life Sciences Center board, bridging public policy and biotech.

p•••@missionbiocapital.comreveal

Barry Selick· Venture Partner

Brook Byers· Partner, Kleiner Perkins Caufield & Byers (Investment Advisory Committee)· San Francisco Bay Areain

Brook Byers has worked as a venture capital investor since 1972, spending his career at Kleiner Perkins, where he is a founder. In 1984 he created the first life sciences practice group in the venture capital profession, steering the firm into healthcare and biotechnology. He has helped build more than 60 technology-based companies and served as founding president or chairman of four biotech companies incubated in Kleiner Perkins' offices that went public with an aggregate market value exceeding $8 billion. His current board work spans companies including Arsenal Bio, Octave Bio, Newsela and Verana Health, and he was a founder of TechNet.

Camille Samuels· Partner, Venrock (Investment Advisory Committee)

Member of Mission Bay Capital's Investment Advisory Committee; Partner at Venrock.

Greg Yap· Partner, Menlo Ventures (Investment Advisory Committee)

Member of Mission Bay Capital's Investment Advisory Committee; Partner at Menlo Ventures.

Jack Wadsworth

Member of Mission Bay Capital's investment advisory committee.

John Wadsworth, Jr· Managing Director, Manitou Ventures (Investment Advisory Committee)

Member of Mission Bay Capital's Investment Advisory Committee; Managing Director at Manitou Ventures.

Jonathan Root· General Partner, US Venture Partners (Investment Advisory Committee)· Menlo Park, Californiain

A board-certified neurologist and physician, Jon Root evaluates medical and biotech investments with a clinical practitioner's perspective. He joined USVP in 1995 as a Kauffman Fellow and became a general partner in 1997, previously serving on the faculty at The New York Hospital-Cornell Medical Center.

j•••@usvp.comreveal

Linda Eng· Office Manager, Mission Bay Capital

Office Manager for Mission Bay Capital supporting deal tracking, meetings, and administration, and Business Manager for the QB3@953 lab incubator. Previously held program management roles at UCSF cancer research programs.

Vivian Dang· Controller / part-time CFO· San Francisco Bay Areain

Brings over 17 years of finance and taxation experience, serving as part-time CFO handling finance and operations since 2010. Previously a controller at Mohr Davidow Ventures and began her career at Andersen and Deloitte.

Wende Hutton· General Partner, Canaan Partners (Investment Advisory Committee)· Menlo Park, Californiain 𝕏

Wende Hutton is a General Partner at Canaan Partners, where she has invested for over 25 years across medtech, biopharma, and healthcare IT. She began her career at Nellcor (now Medtronic), spent two years in operations at a biotech company, and made biopharma investments at Mayfield Fund before joining Canaan in 2004 as a medtech specialist. She studied human biology and physiology in college and takes a hands-on approach to building teams and strategy at her portfolio companies.

w•••@canaan.comreveal

Douglas Crawford· Managing Director· San Francisco, Californiain

Douglas Crawford, an investor who founded MBC BioLabs, builds plug-and-play co‑working wet‑lab incubators that provide turnkey lab space, equipment and mentorship, removing operational friction so founders can begin experiments.

d•••@missionbiocapital.comreveal

Founder mafia

3 people who came through Mission Bay Capital went on to found or lead other companies.

Brook ByersPartner, Kleiner Perkins Caufield & Byers (Investment Advisory Committee)Founded Insite Vision +1 Badreddin EdrisSummer AssociateFounded Silverback Therapeutics +1 Richard YuPrincipalFounded Abalone Bio

What they invest in

from 26 of 34 portfolio companies

Biotech ×21Medical Devices ×12Healthtech ×11Deep Tech ×6AI & Machine Learning ×2Longevity ×2Consumer ×1Creator Economy ×1

HQs:United States×22

Who they back

founder profiles across 15 portfolio companies

47%

solo founders

7 of 15 mapped founding teams

50%

repeat founders

of 14 founders with career history

Founding team size:solo founder×72 founders×23 founders×34+ founders×3

Where their founders studiedfrom 13 founders with education data

Harvard University ×4University of California, Berkeley ×2

What their founders studiedfrom 12 founders with field-of-study data

Life Sciences ×6Chemistry ×2

Where their founders worked beforefrom 14 founders with career history

Stanford University ×2

Investments · 34 tracked

founders shown can be your intro path

By year:2023 · 1 2020 · 1 2016 · 1 2015 · 14 dated

Alectoralector.com in 𝕏NASDAQ: ALECSep 2015

Alector develops therapies targeting neurodegenerative diseases including Alzheimer's, frontotemporal dementia, and Parkinson's disease through protein removal, replacement, and immune cell restoration.

AI & Machine LearningBiotechHealthtechLongevityMedical DevicesSan Francisco, US

Arnon Rosenthal(Ph.D.)inTillman Gerngross(Director)Arnon Rosenthal PhD(Founder)in

BoardCarl Gordon(Director)Terry McGuire(Director)in

Co-investorsForesite Capital Mission Biocapital MRL Ventures Fund SV Health Investors Polaris Partners

Caribou Biosciencescariboubio.com in 𝕏NASDAQ: CRBU

Caribou Biosciences is a clinical-stage biopharmaceutical company developing CRISPR genome-editing therapies, including off-the-shelf CAR-T cell therapies for hematologic malignancies and armored cell therapies using its Cas12a chRDNA platform.

BiotechMedical DevicesBerkeley, US

Jennifer Doudna(Co-founder)Rachel Haurwitz(President and Chief Executive Officer, Co-founder)inMartin Jinek(Co-founder)Andrew May(Executive Officer)

Board Jenny Rooke(Director)in Robert Weisskoff(Director)in

Co-investorsAliment Capital Avego BioScience Capital F-Prime Capital IA Seed Ventures Mission Biocapital Pontifax AgTech +2 more

Alessa Therapeuticsalessatherapeutics.com in

Alessa Therapeutics develops a proprietary drug-delivery platform for sustained and localized release of therapies to treat early-stage prostate cancer.

BiotechHealthtechMedical DevicesSan Carlos, US

Pamela Munster(Founder, Director & Chief Scientific Advisor)inCam Gallagher(President & Chief Executive Officer)inJohn Maroney(Executive Officer, Director)in

Board Zachary Collins(Executive Officer)in Steve Tregay(Director)in Annie Mitsak(Director)in

Co-investorsCure Ventures Mission Biocapital

Applaud Medicalapplaudmedical.com in

Avvio Medical develops Microbubble SonoLithotripsy, a minimally invasive outpatient procedure that uses low-intensity ultrasound to break down ureteral stones without requiring general anesthesia or stents.

Deep TechHealthtechMedical DevicesSan Francisco, US

Co-investorsBaruch Future Ventures Berkeley Catalyst Mission Biocapital

Asher Bioasherbio.com in 𝕏

Asher Bio develops selective immunotherapy drugs that target specific immune cell types to promote beneficial effects while minimizing toxicity.

BiotechHealthtechMedical DevicesSan Francisco, US

Ivana Djuretic(Founder)inAndy Yeung(Founder)inYik Andy Yeung(Executive Officer, Director, Promoter)

Co-investorsEmles Venture Partners GoAhead Ventures Mission Biocapital RA Capital Y Combinator Alexandria +4 more

Atrecaatreca.com

BiotechRedwood City, US

William Robinson(Director)Lawrence Steinman(Director)Tito Serafini(Executive Officer, Director)

BoardBrian Atwood(Director)Franklin Berger(Director)

Co-investorsAisling Capital EcoR1 Capital Evolution VC Partners Mission Biocapital

Bolt Threadsboltthreads.comDefunct

Bolt Threads was a manufacturer of biomaterials for personal care formulations.

BiotechNew MaterialsFoxboro, US

Ethan Mirsky(Executive Officer)David Breslauer(Executive Officer, Director)Daniel Widmaier(Executive Officer, Director)

BoardJerry Fiddler(Director)Steven Vassallo(Director)inJim Kim(Director)

Co-investorsKicker Ventures Kyber Knight Capital Mission Biocapital 8VC Baillie Gifford East West Capital Limited +4 more

Cell Design Labscelldesignlabs.com

BiotechLafayette, US

Peter Emtage(Executive Officer)inGreg Giotta(Executive Officer)Brian Atwood(Executive Officer, Director, Promoter)

BoardFred Cohen(Executive Officer, Director, Promoter)Brook Byers(Director)inArie Belldegrun(Director)

Co-investorsKleiner Perkins OUP (Osage University Partners)

Chrono Therapeuticschronothera.comAug 2016

HealthtechHayward, US

GUY DIPIERRO(Director)inALAN LEVY, PH.D.(Executive Officer, Director)ANTHONY RIMAC(Executive Officer)ALAN LEVY(Executive Officer, Director)

BoardELIZABETH ROCKETT(Director)WENDE HUTTON(Director)in

Co-investorsEmergent Medical Partners, LLP Fountain Healthcare Partners Kaiser Permanente Ventures 5AM Ventures Canaan Partners GE Ventures

Circle Pharmacirclepharma.com

Circle Pharma develops cancer treatments using macrocycle therapies designed to reduce side effects compared to conventional therapies.

BiotechDigital HealthHealthtechMedical DevicesSouth San Francisco, US

Matthew P. Jacobson(Co-founder)Scott R. Lokey(Director)David J. Earp(President & CEO)inPaul Park(Executive Officer)

Board Thilo Schroeder(Director)in Walter H. Moos(Director)

Co-investorsBerkeley Catalyst Hemisphere Ventures LLC Lifeforce Capital Mission Biocapital Nextech Invest Pandect Bioventures +2 more

Dren Biodrenbio.com

Dren Bio is a clinical-stage biopharmaceutical company developing novel antibody therapeutics designed to selectively eliminate pathogenic cells and disease-causing agents, with a pipeline targeting oncology, autoimmune diseases, immunology, and neurology.

BiotechHealthtechMedical DevicesFoster City, US

Nenad Tomasevic(Chief Executive Officer, Founder)

BoardIvan Trifunovich(Director)John Wesley(Director)

Co-investors8VC Aisling Capital Mission Biocapital Olive Tree Capital SR One Capital Management Taiho Ventures, LLC +3 more

Effector Therapeuticseffector.com

eFFECTOR Therapeutics was a clinical-stage biopharmaceutical company.

BiotechSolana Beach, US

Stephen F. Worland, Ph.D.(Executive Officer, Director)Alana McNulty(Executive Officer)in

BoardSimeon George(Director)Jonathan Root(Director)inKen Haas(Director)Laurence Lasky(Director)

Co-investorsAstellas Venture Management LLC Mission Biocapital OUP (Osage University Partners)Pfizer Venture Investments US Venture Partners Sofinnova Ventures

Epiodyneepiodyne.com in

Epiodyne develops small-molecule opioids designed to optimize therapeutic outcomes, with initial focus on safer pain relief and improved opioid use disorder treatment with reduced addiction and respiratory depression risk.

BiotechHealthtechMedical DevicesSan Francisco, US

Brian Shoichet(Director)Douglas Crawford, Ph.D.(CEO)Don Gehlert, Ph.D.(Head of Biology)in

Board Douglas Crawford(Executive Officer, Director)in

Co-investorsMenlo Ventures Mission Biocapital Kleiner Perkins

Fluxionfluxionbio.com inacquired by Cell Microsystems

BiotechDeep TechHardware

Co-investorsClaremont Creek Ventures Mission Biocapital Signet Healthcare Partners

Glycomine www.glycomine.comglycomine.com in 𝕏

Glycomine develops therapeutics for rare diseases, many of which currently lack disease-modifying treatment options.

Biotech

Steven Axon(Chief Executive Officer)in Hicham Alaoui(Chief Scientific Officer)inRose Marino(Chief Medical Officer)in Peter McWilliams(Chief Business Officer)Geoffrey Hird(Chief Technology Officer)in

Co-investorsAdvent Life Sciences Mission Biocapital Remiges Ventures, Inc.RiverVest Venture Partners Sanderling Ventures Sanofi Ventures

Invenioinvenio-imaging.com in 𝕏

Invenio develops rapid on-site tissue imaging systems combined with AI to improve cancer patient care.

AI & Machine LearningBiotechDeep TechMedical DevicesSanta Clara, US

Jay Trautman(President & CEO, Co-Founder)in Chris Freudiger(Chief Technology Officer, Co-Founder)inChristian Freudiger(Director)inXiaoliang Xie(Director)

Board Doug Crawford(Director)in

Co-investorsBerkeley Catalyst Mission Biocapital

Kitkit.com in 𝕏

Kit provides email marketing and commerce tools for creators and independent businesses to reach audiences and monetize their work through newsletters and storefronts.

Creator EconomyMarketing TechSaaS

Nathan Barry(Founder + CEO)in

Co-investorsAUTHENTIC VENTURES Brighter Capital Expa Mission Biocapital WAGMI Ventures Oceans Ventures +1 more

Mammoth Biosciencesmammoth.bio in 𝕏

Mammoth Bio develops technology to read and write the code of life, operating in the biotechnology sector.

BiotechDeep TechMedical DevicesBrisbane, US

Jennifer Doudna(Founder)in Trevor Martin(Co-founder, Chief Executive Officer)in Janice Chen(Co-founder, Chief Scientific Officer & President, Research)in Lucas Harrington(Co-founder)in Ashley Tehranchi(Executive Officer, Director)in

BoardUrshit Parikh(Director)

Co-investors8VC Berkeley Frontier CALIFORNIA INNOVATION Decheng Capital Foresite Capital Mayfield Fund +9 more

Mpmcapitalmpmcapital.com in 𝕏

MPM Capital is a venture capital and life sciences investment firm that backs companies in biotech, therapeutics, and healthcare innovation, with a focus on translating scientific research into transformative medicines and treating severe diseases.

Biotech

Ansbert Gadicke(Chairman)in Chris Bardon(Managing Partner)in

multi-step chainsberkeley.edu in 𝕏

Berkeley, US

Co-investorsAutodesk Foundation AVA Angels Berkeley SkyDeck Fund CRV (Charles River Ventures)Melbourne Accelerator Program (MAP)Moonhill Capital+1 more

Nitrase Therapeuticsnitrasetx.com in

Nitrase Therapeutics is a clinical-stage biopharmaceutical company using its NITROME platform to develop therapeutics based on nitrases, a class of enzymes it discovered that drive protein nitration.

BiotechHealthtechLongevity

Irene Griswold-Prenner(Founder & Chief Executive Officer)in

Co-investorsMission Biocapital Sofinnova Partners AbbVie Dementia Discovery Fund

Pionyr Immunotherapeuticspionyrtx.com in

HealthtechSan Francisco, US

Matthew F. Krummel, Ph.D.(Director)Steven P. James(Executive Officer, Director, Promoter)inLeon Chen, Ph.D.(Director)Carol Gallagher(Director)inJoshua Resnick, M.D.(Director)

BoardMichael Powell(Director)

Co-investorsMission Biocapital New Enterprise Associates (NEA)OUP (Osage University Partners)Sofinnova Ventures OrbiMed Sofinnova Venture Partners

Principia Biopharmaprincipiabio.com

BiotechSouth San Francisco, US

MARTIN BABLER(Executive Officer, Director)in

Board PETER THOMPSON(Director)in SRINIVAS AKKARAJU(Director)MICHAEL DYBBS(Director)inSIMEON GEORGE(Director)LEWIS J. SHUSTER(Director)

Co-investorsAccess Biotechnology Mission Biocapital Sofinnova Ventures New Leaf Venture Partners OrbiMed Samsara BioCapital +1 more

Quralisquralis.com in 𝕏Mar 2023

QurAlis develops precision therapies for amyotrophic lateral sclerosis (ALS) and related neurodegenerative diseases by targeting specific disease-causing genetic drivers and molecular mechanisms.

BiotechDeep TechMedical DevicesCambridge, US

Kevin Eggan(Co-founder)inRoet(Co-founder)Woolf(Co-founder)Kasper Roet(Director, Executive Officer, Promoter)in Shafique Virani(Executive Officer)in Jason Brown(Mr. Brown is the Chief Financial Officer of the Issuer.)in

Co-investorsDolby Family Ventures Droia Ventures MC Healthcare Ventures Mission Biocapital Mitsui Global Investment Sanofi Ventures +7 more

Symbiomesymbiome.comSep 2020 · $15M

Symbiome develops skin microbiome-based wellness products that restore ancestral skin health through proprietary fermentation and Amazonian botanical ingredients.

ConsumerHealthtechWellness & FitnessSan Francisco, US

Larry Weiss(Executive Officer, Director)Adam Klausner(Executive Officer)Vicki Levine(Executive Officer, Director)

Board Adam D'Augelli(Director)in

Co-investorsBold Capital Partners Mission Biocapital GISEV Family Office True Ventures

Vederevederebio.com

Vedere Bio develops optogenetics-based gene therapies for inherited retinal diseases (IRDs) and geographic atrophy (GA), using proprietary AAV vectors for intravitreal administration to restore vision in visually impaired patients globally.

BiotechDeep TechMedical DevicesCambridge, US

Co-investorsMission Biocapital

Other

Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.

Alpine RoadsAmbagon TherapeuticsAvexegenCalitheraGraphwearLogicViewPoint Therapeuticsvisit www.mitokinin.com

Exits · 3

2 IPOs · 1 acquisitions

AlectorNASDAQ: ALECCaribou BiosciencesNASDAQ: CRBUFluxionacq. by Cell Microsystems

Portfolio news

latest coverage across their companies

Alessa Therapeutics Announces Closing $15M Seed Financing | Alessa Therapeutics

Alessa Therapeutics · alessatherapeutics.com · Oct 21, 2025

Fund performance · per public LP disclosures · 2

as of Jun 2025

Fund	Vintage	Committed	Net IRR	TVPI	DPI
Mission Bay Capital IIILPs: The Regents of the University of California	2018	—	21.8%	2.11x	0.28x
Mission Bay Capital IILPs: The Regents of the University of California, Sobrato Family Foundation	2015	—	14.7%	2.35x	0.98x

Source: public limited-partner disclosures (CalPERS, CalSTRS). Net IRR / TVPI / DPI as reported by the limited partner; a fund's early-year IRR is an interim estimate (J-curve).

Frequently asked questions

How many investments has Mission Bay Capital made?: Mission Bay Capital has 34 tracked investments, 3 of which have exited.
What stage does Mission Bay Capital invest at?: Mission Bay Capital invests at the Pre-Seed, Seed, Series A, Late Stage stages.
What sectors does Mission Bay Capital focus on?: Mission Bay Capital focuses on Biotech, Climate Tech, Deep Tech, Healthtech, Medical Devices.
Where is Mission Bay Capital located?: Mission Bay Capital is headquartered in San Francisco, US.
Who does Mission Bay Capital co-invest with?: Mission Bay Capital most often shares deals with Mission Biocapital, Berkeley Catalyst, OUP (Osage University Partners), among 70 tracked co-investors.

Similar investors

Amadeus Capital Partners

Amadeus Capital Partners is a technology investment firm that backs founders building complex, science-led and deep tech businesses, supporting them over the long term as they scale internationally.

$50K – $12.7M

B Capital Group

B Capital is a global investment firm backing early to late-stage technology innovators across technology, healthcare, and energy & resilience sectors.

$10M – $50M

DCVC (Data Collective)

DCVC (Data Collective) is a deep tech venture capital firm that backs entrepreneurs using computational approaches to solve large-scale real-world problems across many industries.

$5M – $25M

Khosla Ventures

Khosla Ventures is a venture capital firm founded by Vinod Khosla.

$5K – $50M

Sofinnova Partners

Sofinnova Partners is a life sciences venture capital firm investing across the value chain from seed to later stage, with a focus on healthcare and sustainability. It backs companies in biopharma, medtech, digital medicine, agriculture and industrial processes.

$540K – $27M